1/29/2008 | SS | Acquisition of Adams Respiratory Therapeutics by Reckitt Benckiser completed
|
1/24/2008 | SS | Reckitt Benckiser accepts 95.9% of Adams Respiratory shares in tender offer
|
1/22/2008 | SS | Gamco, Gabelli buy 8.16% stake in Adams Respiratory
|
1/7/2008 | SS | HSR wait ends for Reckitt Benckiser, Adams Respiratory merger
|
12/21/2007 | SS | Reckitt Benckiser begins tender offer for Adams Respiratory
|
12/10/2007 | SS | Market Commentary: Washington Mutual restructures; UBS, MBIA get cash infusions; MGI, Adams merge with foreign drug firms
|
12/10/2007 | SS | Reckitt Benckiser's acquisition of Adams Respiratory to help company grab OTC drug market share
|
11/9/2006 | BT | Adams maintained at outperform by RBC
|
11/8/2006 | BT | Adams Respiratory: first quarter net sales up 92% on strength of Mucinex brand
|
10/19/2006 | BT | Adams gets outperform rating from RBC
|
10/5/2006 | BT | RBC ups Adams Respiratory to outperform
|
8/25/2006 | BT | Adams Respiratory kept at sector perform by RBC
|
8/24/2006 | BT | Adams reports fourth quarter net income of $6.3 million, up from $79.0 million net loss in 2005
|
8/21/2006 | BT | Adams Respiratory kept at sector perform by RBC
|
8/18/2006 | BT | Adams faces possible generic Mucinex fight
|
8/9/2006 | BT | Adams Respiratory kept at sector perform by RBC
|
7/27/2006 | BT | Adams to repurchase manufacturing assets, operations from Cardinal Health
|
7/27/2006 | BT | RBC maintains Adams at sector perform
|
7/27/2006 | BT | Market Commentary: Adams hit 4%; Conor slips after follow-on; Diomed pockets $10 million from PIPE; Oscient gains
|
7/17/2006 | BT | Adams Respiratory gets five-year $50 million credit facility
|
6/9/2006 | BT | RBC puts Adams Respiratory at sector perform
|
6/2/2006 | BT | RBC keeps target for Adams
|
5/26/2006 | BT | Adams Respiratory rated at perform by RBC
|
5/24/2006 | BT | Adams buys Delsym from UCB for $122 million plus royalty
|
5/11/2006 | BT | Adams Respiratory's net sales up 29% for the quarter at $76 million
|
3/30/2006 | BT | Adams Respiratory starts phase 2 trial of erdosteine for chronic bronchitis
|
3/29/2006 | BT | Merrill keeps Adams Respiratory at neutral
|
2/8/2006 | BT | Merrill rates Adams at neutral
|
1/3/2006 | BT | Adams Respiratory may lose Mucinex delivery system patent
|
1/3/2006 | BT | Adams Respiratory still neutral, Merrill says
|
1/3/2006 | BT | Market Commentary: Adams declines; Alkermes gains; Cephalon up; Indevus off; Wyeth up, Bradley off, ViroPharma rises
|
12/9/2005 | BT | New Issue: Adams secondary of 5.66 million shares prices at $43.75 vs. $44.25 close
|
12/9/2005 | BT | Market Commentary: Adams slides after secondary; Voyager IPO delayed; Cephalon spikes, Teva rises; Genitope up
|
12/7/2005 | BT | Market Commentary: Voyager IPO at bat; Amgen off; ViroPharma jumps after deal; Dendreon slides; Rigel up sharply
|
12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
11/30/2005 | BT | Adams secondary offering of 5.66 million shares launched via Merrill, Morgan; sellers include EGI, Soros
|
11/30/2005 | BT | Market Commentary: Adams secondary launched; Isis off; Durect up; Inspire, BioCryst rocket up; Merck bonds weaker
|
11/10/2005 | BT | Merrill maintains Adams Respiratory at neutral
|
9/7/2005 | BT | Adams initiated by Merrill Lynch at neutral
|
7/28/2005 | BT | Market Commentary: Advanced Life Sciences IPO cut; ZymoGenetics plans follow-on; Elan plunges on credit worries
|
7/25/2005 | BT | Adams Respiratory Therapeutics greenshoe exercised in full, lifting IPO to $106.6 million
|
7/22/2005 | BT | Market Commentary: Momenta gains at open, then goes south; Adams up against market; Durect convertibles up on buyback
|
7/21/2005 | BT | New Issue: Adams Respiratory sells upsized 7.95 million shares at $17 each, above range of $14-$16
|
7/21/2005 | BT | Market Commentary: Adams IPO zooms; Accentia stalls, again; Guilford up on MGI Pharma merger; Momenta on tap; Isis rises
|
7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
7/6/2005 | BT | Adams Respiratory Therapeutics sets IPO price talk at $14 to $16 per share
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|